Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 15th International Pharmaceutical Microbiology and Biotechnology Conference London, UK.

Day 1 :

Keynote Forum

Ana Falcon

National Center for Biotechnology, Spain

Keynote: Severe outcome in influenza virus infected patients is associated with reduced accumulation of defective viral genomes

Time : 10:25-11:00

OMICS International Pharmaceutical Microbiology 2017 International Conference Keynote Speaker Ana Falcon photo

Ana Falcón completed her PhD in Molecular Biology and Science at Autonomous University, Madrid. During her scientific career, she has studied molecular biology of several respiratory viruses of clinical significance as influenza virus, SARS-CoV and other coronaviruses. She has worked on virus reverse genetics, functional analysis of viral and cellular proteins, and molecular diagnosis of virus in clinical samples and on animal models to study viral pathogenesis. She is developing and coordinating an international multidisciplinary project including physicians, microbiologists, molecular virologists and bioinformatics. She is a Reviewer for several scientific journals and has trained PhD and master students.


Influenza A virus (IAV) infection can be severe or even lethal in toddlers, the elderly and patients with certain medical conditions. Infection of apparently healthy individuals nonetheless accounts for many severe disease cases and deaths, suggesting that viruses with increased pathogenicity co-circulate with pandemic or epidemic viruses. Looking for potential virulence factors, we have identified a viral genetic determinant that contributes to infection outcome. A polymerase mutation identified in a fatal IAV case, when introduced into two different recombinant virus backbones, led to reduced defective viral genomes (DGs) production and increased pathogenesis in mice. These data provide genetic support for the association of pathogenicity and low DGs accumulation induced by mutations present in pathogenic viruses circulating in humans. Testing this association, we performed a genomic analysis of viruses isolated from a cohort of previously healthy individuals who suffered highly severe IAV infection requiring admission to intensive care unit, and patients with fatal outcome who additionally showed underlying medical conditions. These viruses were compared with those isolated from a cohort of mild IAV patients. Viruses from highly severe/fatal outcome patients showed significantly fewer DGs accumulation than control viruses, suggesting that low DGs abundance constitutes a new virulence viral pathogenic marker in humans, regardless of the mutations responsible.